Top Page
Imagion Biosystems Ltd.
(Sydney:IBX)
Imagion Biosystems Ltd. (IBX) vs. iShares MSCI Australia ETF (EWA)
Imagion Biosystems Ltd. Business Overview & Revenue Model
Imagion Biosystems Ltd. Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 2.67M | 1.37M | 473.43K | 232.87K | 205.72K |
| Gross Profit | 2.26M | -3.88M | -3.14M | -2.47M | -2.66M |
| EBITDA | -700.09K | -10.30M | -9.49M | -5.90M | -5.19M |
| Net Income | -2.07M | -12.47M | -9.81M | -8.64M | -7.80M |
Balance Sheet | |||||
| Total Assets | 2.80M | 4.59M | 9.98M | 14.12M | 14.12M |
| Cash, Cash Equivalents and Short-Term Investments | 2.67M | 227.08K | 4.45M | 13.39M | 13.20M |
| Total Debt | 2.85M | 6.04M | 4.60M | 46.02K | 660.98K |
| Total Liabilities | 5.09M | 8.37M | 5.30M | 809.88K | 1.21M |
| Stockholders Equity | -2.28M | -3.79M | 4.68M | 13.31M | 12.91M |
Cash Flow | |||||
| Free Cash Flow | -1.27M | -8.51M | -9.21M | -5.29M | -4.63M |
| Operating Cash Flow | -1.27M | -8.32M | -8.70M | -5.07M | -4.62M |
| Investing Cash Flow | 83.74K | -190.38K | -468.73K | -310.09K | -7.86K |
| Financing Cash Flow | 3.61M | 4.29M | -962.06K | 5.15M | 14.52M |
Imagion Biosystems Ltd. Technical Analysis
Imagion Biosystems Ltd. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | 41.98M | 22.28 | 78.86% | 8.14% | 11.93% | 2.39% | |
55 Neutral | 133.60M | -11.49 | 0.00% | ― | 12.96% | 45.59% | |
51 Neutral | AU$9.61M | ― | ― | -47.02% | 94.37% | ||
49 Neutral | 42.42M | -6.10 | 0.00% | ― | 2.33% | 12.50% | |
43 Neutral | 23.79M | -3.28 | 0.00% | ― | 0.00% | 23.85% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
Imagion Biosystems Ltd. Corporate Events
Imagion Biosystems Limited has announced significant progress in its MagSense® HER2 Breast Cancer diagnostic imaging program, with the commencement of manufacturing for the Phase 2 clinical trial. The company has also secured $3.5 million in funding and appointed Dr. Nina Webster as a Non-Executive Director to strengthen its leadership team. Additionally, Imagion has initiated a collaboration with Wayne State University to optimize imaging protocols, supported by Siemens Healthineers, which could enhance the diagnostic utility of its molecular MRI technology.
Imagion Biosystems Limited reported a significant financial loss for the half-year ending June 30, 2025, with no revenue from ordinary activities and an 8.8% increase in losses compared to the previous period. The company did not declare any dividends, and its net tangible assets per ordinary security decreased, reflecting ongoing financial challenges.
Imagion Biosystems Limited has announced an Extraordinary General Meeting (EGM) to be held virtually on September 24, 2025. The company is transitioning to electronic communications for meeting materials, aligning with recent amendments to the Corporations Act 2001. Shareholders are encouraged to submit proxies early and can participate virtually, with provisions made for voting and asking questions during the meeting.
Imagion Biosystems has entered a collaboration with Wayne State University to enhance its molecular imaging capabilities using its MagSense® technology. This partnership, alongside Siemens Healthineers, aims to develop advanced MRI protocols and quantitative imaging techniques that enable AI-based cancer diagnostics. The collaboration is expected to improve diagnostic accuracy, democratize access to advanced imaging, and accelerate the development of AI diagnostics, potentially transforming cancer detection and patient care.
Imagion Biosystems has successfully completed the first tranche of its $3.5 million capital raising, securing $0.675 million through the issuance of 45 million new ordinary shares. The second tranche, expected to raise an additional $2.8 million, is contingent upon shareholder approval at an upcoming Extraordinary General Meeting. This capital raising effort is part of Imagion’s strategy to advance its MagSense® imaging technology, which is designed to improve healthcare outcomes by enabling earlier and more precise detection of cancer cells.
Imagion Biosystems Limited has announced a breakthrough in cancer detection through its Molecular Magnetic Resonance Imaging technology. This advancement is expected to significantly impact the company’s operations by improving its industry positioning and offering stakeholders a promising tool in the fight against cancer.
Imagion Biosystems Ltd. has announced a proposed issue of 45 million ordinary fully paid securities, scheduled for August 6, 2025. This move is part of a placement or other type of issue, potentially impacting the company’s financial standing and market positioning by raising capital for its operations and strategic initiatives.
Imagion Biosystems Limited has requested a trading halt on its securities on the Australian Securities Exchange pending an announcement related to a capital raising initiative. This move is intended to help the company manage its disclosure obligations and is expected to precede a material announcement that could impact its financial strategy and market positioning.
Imagion Biosystems Ltd. has announced the issuance of 1,200,000 unquoted equity securities under an employee incentive scheme, set to expire in May 2030. This move is part of the company’s strategy to incentivize and retain key personnel, potentially impacting its operational dynamics and market positioning by aligning employee interests with long-term company performance.
Imagion Biosystems Ltd. has made significant progress in its MagSense® HER2 breast cancer imaging agent program, aiming to file an Investigational New Drug (IND) application for a Phase 2 clinical trial with the FDA in the third quarter of 2025. The company received positive feedback from the FDA, boosting confidence in the IND submission. Additionally, Imagion has entered into a Master Service Agreement with Biosensis Ltd. to manage costs and advance nanoparticle research, and appointed Dr. Leonardo Kayat-Bittencourt as a clinical advisor for its prostate cancer program. The company is also preparing for the manufacturing of the MagSense® HER2 imaging agent and has selected Dr. William Dooley as the Principal Investigator for the upcoming study. Financially, Imagion reported a decrease in cash balance and operating cash outflows, with plans to reduce corporate costs and focus funds on the IND application.